[Antibody-targeted radio-chemotherapy of human primary liver cancer with radio-iodinated AFP monoclonal antibodies conjugated with mitomycin C: a preliminary clinical observation].
A "dual-warhead missile" made of 131I-AFP monoclonal antibody conjugated with mitomycin C was prepared. Twelve patients with moderately advanced and advanced primary liver cancer (PLC) were treated by i.v. injection of the antibody preparation. Tumor decrease in size was observed in 45.5% of the treated patients and decline in serum AFP level was seen in 83.3%. The one-year survival rate was 45.5%. Antibody-targeted radio-chemotherapy is a treatment of choice for advanced PLC patients.